| Lenvima (lenvatinib) / Eisai, Merck (MSD) |
ChiCTR2100046490: TACE plus Lenvatinib versus TACE Plus Sorafenib for Unresectable Hepatocellular Carcinoma with Portal Vein Tumor Thrombus |
|
|
| Completed | 4 | 100 | | Lenvatinib ;Sorafenib | West China Hospital, Sichuan University; West China Hospital, Department of Science and Technology of Sichuan Province of China (21YYJC2782) and Health Commission of Sichuan Province (20PJ043) | Liver Cancer | | | | |
NCT06195228: A Retrospective and Prospective Real-world Study of Molecular Typing in the Treatment of Advanced Thyroid Cancer |
|
|
| Recruiting | 4 | 200 | RoW | dabrafenib plus trametinib with or without PD-1 antibody, entrectinib or larotrectinib with or without anti-PD-1 antibdoy, pralsetinib or selpercatinib with or without anti-PD-1 antibdoy, anlotinib or anlotinib plus anti-PD-1 antibody, lenvatinib plus anti-PD-1 antibody, Other Targets: precise treatment based on the target | Fudan University, Inner Mongolia Cancer Hospital Affiliated To Inner Mongolia Medical University, Shanxi Province Cancer Hospital | Advanced Thyroid Cancer Patients Who Received Target Therapy | 04/26 | 04/27 | | |
ChiCTR2000034143: Prospective, single-arm, multicenter clinical study of lenvatinib for adjuvant treatment of HCC patients with high risk of recurrence after hepatectomy. |
|
|
| Recruiting | 4 | 164 | | Lenvatinib | Nangfan Hospital; Nanfang Hospital, Cheng Xiao-ping foundation for the development of science and technology of Hubei province | Hepatocellular Carcinoma | | | | |
ChiCTR1900023914: A study of PD-1/PD-L1 inhibitors combined with Lenvatinib for advanced unresectable liver cancer as the neoadjuvant therapy |
|
|
| Recruiting | 4 | 80 | | combination of anti-pd-1 / pd-l1 antibody and Lenvastinib; anti-pd-1 / pd-l1 antibody or Lenvastinib ;neither of anti-pd-1 / pd-l1 antibody or Lenvastinib | Department of Hepatobiliary Surgery Chinese PLA General Hospital & Medical School; Chinese PLA General Hospital & Medical School, Self-fund | Hepatocellular carcinoma | | | | |
NCT04127396: Lenvatinib Plus TACE Versus Sorafenib Plus TACE for HCC With PVTT |
|
|
| Enrolling by invitation | 4 | 72 | RoW | Lenvatinib Pill, E7080, Transarterial chemoembolization(TACE), Sorafenib | Beijing Ditan Hospital | Carcinoma, Hepatocellular, Portal Vein Tumor Thrombus | 08/21 | 12/21 | | |
ChiCTR2100054077: Efficacy and safety of Zimberelimab plus Lenvatinib as first-line treatment in unresectable or metastatic hepatocellular carcinoma patients: a single arm, prospective clinical study |
|
|
| Recruiting | 4 | 32 | | Zimberelimab plus Lenvatinib | Jiansu Cancer Hospital; Jiansu Cancer Hospital, self-funded | Hepatocellular Carcinoma | | | | |
ChiCTR2200059078: A prospective, small sample and observational study of TACE combined with portal vein tumor thrombus seed implantation and Lenvatinib in the treatment of HCC with portal vein tumor thrombus |
|
|
| Not yet recruiting | 4 | 30 | | TACE combined with particle implantation combined with Lenvatinib | Henan Cancer Hospital; Henan Cancer Hospital, Self-financing | Hepatocellular Carcinoma with Portal Vein Canc | | | | |
ChiCTR1900027953: A multicenter prospective cohort study for relapse prevention in patients with high-risk recurrence after primary hepatocellular carcinoma resection |
|
|
| Recruiting | 4 | 412 | | Lenvatinib ;Blank | Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University; Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University, Guangdong Medical Doctor Association | Hepatocellular carcinoma | | | | |
ChiCTR2000033343: A prospective randomized controlled clinical study of the efficacy of lenvatinib combined with TACE versus TACE alone in patients with advanced first-line unresectable hepatitis B infection |
|
|
| Not yet recruiting | 4 | 176 | | Lenvatinib combined with TACE ;TACE | The First Affiliated Hospital of Zhejiang University; The First Affiliated Hospital of Zhejiang University, Patients purchase medicines at their own expense, hospital scientific research funding | Hepatocellular carcinoma | | | | |
NCT04297254: A Study to Assess the Safety and Efficacy of Lenvatinib as First-line Treatment in Participants With Unresectable HCC |
|
|
| Completed | 4 | 50 | RoW | Lenvatinib | Eisai Pharmaceuticals India Pvt. Ltd | Carcinoma, Hepatocellular | 07/23 | 07/23 | | |
ChiCTR2200056181: Single-arm and exploratory clinical study of lenvatinib, tirelizumab and radiotherapy combined with HAIC in the treatment of hepatocellular carcinoma with portal vein tumor thrombus |
|
|
| Recruiting | 4 | 38 | China | Lenvatinib+Tislelizumab+Radiotherapy + Hepatic Artery Infusion Chemotherapy (HAIC) | Zhongshan Hospital Xiamen University; Zhongshan Hospital Xiamen University, self-funded | Hepatocellular carcinoma | | | | |
ChiCTR2100042270: A prospective, randomized controlled, open-label clinical study of lenvatinib + camrelizumab + TACE +versus lenvatinib + camrelizumab in the treatment of advanced liver cancer |
|
|
| Recruiting | 4 | 58 | | lenvatinib + camrelizumab +TACE ;lenvatinib + camrelizumab | Affiliated Tumor Hospital of Guangxi Medical University; Affiliated Tumor Hospital of Guangxi Medical University, self-raised | Primary liver cancer | | | | |
NCT06311929: Precision Adjuvant Therapy After Surgery for Hepatocellular Carcinoma |
|
|
| Recruiting | 4 | 300 | RoW | PD-1 monoclonal antibody and lenvatinib, Non, PD-1 monoclonal antibody | Chen Xiaoping | HCC | 12/27 | 12/28 | | |
NCT06311942: Triple vs. Dual Adjuvant Therapy Following Liver Resection for HCC. |
|
|
| Recruiting | 4 | 300 | RoW | HAIC plus PD-1 inhibitors plus lenvatinib, Non, PD-1 inhibitors plus lenvatinib | Chen Xiaoping | HCC | 12/27 | 12/28 | | |
NCT03573960: A Study to Evaluate the Safety and Efficacy of Lenvatinib in Participants With Refractory Differentiated Thyroid Cancer |
|
|
| Active, not recruiting | 4 | 50 | RoW | Lenvatinib | Eisai Pharmaceuticals India Pvt. Ltd | Thyroid Neoplasms | 12/24 | 12/24 | | |
NCT06311916: Efficacy and Safety of Neoadjuvant Therapy in Patients With Resectable HCC Screened by a Multimodal Deep Learning Model. |
|
|
| Not yet recruiting | 4 | 312 | NA | HAIC + Tirelizumab +lenvatinib +liver resection, Non, liver resection | Chen Xiaoping | HCC | 12/27 | 12/28 | | |
NCT06417606: Lenvatinib and Adebrelimab Combined With GEMOX in the Perioperative Treatment of Potentially Resectable Intrahepatic Cholangiocarcinoma |
|
|
| Not yet recruiting | 4 | 20 | RoW | Lenvatinib, Adebrelimab, GEMOX（Gemcitabine and oxaliplatin） | Zhiyong Huang | Intrahepatic Cholangiocarcinoma | 04/25 | 05/25 | | |
NCT05673824: Effect of Huaier Granule on Nephrotoxicity Associated With Targeted Therapy for Advanced Hepatobiliary Malignancies. |
|
|
| Recruiting | 4 | 53 | RoW | Huaier Granule, VEGFR-TKIs | Fudan University, LinkDoc Technology (Beijing) Co. Ltd. | Nephrotoxicity | 02/25 | 04/25 | | |
ChiCTR2100047099: A single center real-world study of Lenvatinib in the treatment of locally advanced differentiated thyroid cancer |
|
|
| Recruiting | 4 | 12 | | Nil | Fujian Cancer Hospital; Fujian Cancer Hospital, self-funded | differentiated thyroid cancer | | | | |
NCT06003673: A Clinical Study of Tislelizumab Combined With TACE and Lenvatinib in the Neoadjuvant Treatment of Resectable HCC |
|
|
| Recruiting | 4 | 20 | RoW | neoadjuvant therapy | First Affiliated Hospital of Fujian Medical University | Hepatocellular Carcinoma Resectable | 07/24 | 07/25 | | |
ChiCTR2200061888: An exploratory study of pembrolizumab combined with lenvatinib mesylate for first-line treatment of advanced hepatocellular carcinoma |
|
|
| Not yet recruiting | 4 | 43 | China | Pembrolizumab in combination with lenvatinib | Tangdu Hospital, Air Force Military Medical University ; Tangdu Hospital, Air Force Military Medical University, self-funded | hepatocellular carcinoma | | | | |
NCT06499610: Clinical Study of Irinotecan Liposome Combination Therapy for Advanced Gastric Cancer |
|
|
| Not yet recruiting | 4 | 44 | RoW | Irinotecan Hydrochloride Liposome Injection, Sintilimab Injection, Lenvatinib Mesilate Capsules | First Affiliated Hospital Xi'an Jiaotong University | Gastric Cancer | 10/27 | 10/27 | | |
ChiCTR2000035161: Single arm clinical study of Lenvatinib combined with Camrelizumab as the first-line treatment of advanced hepatocellular carcinoma |
|
|
| Recruiting | 4 | 72 | | Lenvatinib combined with Camrelizumab | Guangdong General Hospital; Guangdong General Hospital, Bethune Charitable Foundation; Heart to Heart Foundation | hepatocellular carcinoma | | | | |
ChiCTR2200057630: A randomized, open label, controlled trial for Arsenic trioxide combined with Lenvatinib in the treatment of advanced unresectable hepatocellular carcinoma |
|
|
| Not yet recruiting | 4 | 146 | | Renvatinib ;Renvatinib + Arsenic Trioxide | Shanghai Changhai Hospital; Changhai Hospital, Shanghai Special Project of Integrated Traditional Chinese and Western Medicine | hepatocellular carcinoma | | | | |
ChiCTR2100052881: A clinical study of hepatic artery infusion chemotherapy combined with lenvatinib bridging therapy before liver transplantation for primary hepatic carcinoma exceeding milan criteria |
|
|
| Recruiting | 4 | 30 | | HAIC(hepatic artery infusion chemotherapy) combined with Lenvatinib | The Third Affiliated Hospital of Sun Yat-Sen University; The Third Affiliated Hospital of Sun Yat-Sen University, The Bethune Liver Cancer Research Program | Primary hepatic carcinoma | | | | |
| Not yet recruiting | 4 | 30 | Europe | Olaparib, Lynparza, Lenvatinib, Lenvima, Sunitinib, Sutent, Palbociclib, Ibrance, Pazopanib, Votrient | University Medical Center Groningen | Renal Cell Carcinoma, Ovarian Carcinoma, Thyroid Carcinoma, Breast Carcinoma, Endometrium Carcinoma | 03/25 | 03/25 | | |
ChiCTR2300069480: Transformation therapy of locally advanced gallbladder cancer with camrelizumab combined with lenvatinib: a single-center, single-arm, exploratory clinical study |
|
|
| Not yet recruiting | 4 | 25 | | Preoperative: Karelizumab 200 mg q2w, orally administered with rivatinib once daily for 2-8 cycles. Evaluate the efficacy every 2 cycles, and then perform surgery; Postoperative: Original adjuvant therapy, up to one year | Qingdao University Affiliated Hospital; The Affiliated Hospital of Qingdao University, self-funded | Cholangiocarcinoma | | | | |
ChiCTR2300073121: Camrelizumab combined with TACE and targeted therapy VS TACE combined with targeted therapy for primary hepatocellular carcinoma with portal vein tumor thrombus: a comparative study |
|
|
| Not yet recruiting | 4 | 78 | | Carrelizumab combined with D-TACE and targeted therapy, this group of patients received D-TACE and intraoperative intraoperative intravenous infusion of carrelizumab 200 mg, and oral lenvatinib 8 mg QD (body weight < 60 kg) or 12 mg QD (body weight >=60 kg) was started on days 3 to 7 after D-TACE according to the patient's recovery. Carrelizumab 200 mg IV is given every three weeks. In the first half of the year, blood and imaging tests are routinely reviewed every 4-8 weeks, and D-TACE treatment is repeated as needed according to the results of the review. If the patient's condition is stable, the interval between re-examination will be extended after six months according to the actual situation. ;The patients in this group were treated with 8 mgQD (body weight < 60kg) or 12 mgQD (body weight >= 60kg) on the 3-7 days after D-TACE. | The First Affiliated Hospital, Zhejiang University School of Medicine; The First Affiliated Hospital, Zhejiang University School of Medicine, BEIJING MEDICAL AWARD FOUNDATION | primary hepatocellular carcinoma with portal vein tumor thrombus | | | | |
ChiCTR2300068266: Tirelizumab plus Lunvatinib and capecitabine for first-line treatment of advanced intrahepatic cholangiocarcinoma unsuitable for GP chemotherapy |
|
|
| Not yet recruiting | 4 | 36 | China | 1. Tirelizumab: 200mg, q3w, intravenous drip, lasting for 1 year, or until the disease progresses or intolerable adverse reactions occur; 2. Remvastinib: 8mg, qd, oral, until the disease progresses or intolerable adverse reactions occur; 3. Capecitabine: 1000mg/m2, bid, oral, take it for 2 weeks, stop for 1 week | The Third Affiliated Hospital of Naval Medical University (Eastern Hepatobiliary Surgery Hospital) ; The Third Affiliated Hospital of Naval Medical University (Eastern Hepatobiliary Surgery Hospital), BeiGene (Beijing), Ltd. | advanced intrahepatic cholangiocarcinoma | | | | |
ChiCTR2300071610: A prospective study of the effect of preoperative neoadjuvant therapy of Lenvatinib combined with Camrelizumab on prognosis of patients with high risk of recurrence of hepatocellular carcinoma |
|
|
| Not yet recruiting | 4 | 60 | | Preoperative adjuvant medication | Mengchao Hepatobiliary Hospital of Fujian Medical University; Mengchao Hepatobiliary Hospital of Fujian Medical University, self-funded | Hepatocellular carcinoma | | | | |
| Recruiting | 4 | 56 | | High-dose irradiation plus low-dose radiatlion combined with tislelizumab and lenvatinib | Pingxiang People's Hospital; Pingxiang People's Hospital, Pingxiang People's Hospital | hepatocellular carcinoma | | | | |
ChiCTR2300076540: A multicenter, prospective, exploratory research study of modified DEB-TACE in the treatment of unresectable large liver cancer in Shandong |
|
|
| Not yet recruiting | 4 | 78 | | Modified DEB-TACE+Lenvatinib+Camrelizumab | Linyi Cancer Hospital; Linyi Cancer Hospital, raised independently | Hepatocellular carcinoma | | | | |
2020-004437-20: A clinical study to compare Toripalimab (JS001) combined with Lenvatinib versus placebo combined with Lenvatinib as the 1st-line therapy for advanced hepatocellular carcinoma (HCC) |
|
|
| Ongoing | 3 | 519 | Europe | Toripalimab, LENVIMA, TAB001 and JS001, Solution for infusion, Capsule, hard, LENVIMA | Shanghai Junshi Biosciences Co., Ltd, Shanghai Junshi Biosciences Co., Ltd., Shanghai Junshi Biosciences Co., Ltd | advanced hepatocellular carcinoma (HCC), liver cancer, Diseases [C] - Cancer [C04] | | | | |
2018-002520-16: Pembrolizumab plus Lenvatinib as First-line Intervention for Advanced Melanoma |
|
|
| Not yet recruiting | 3 | 790 | Europe, RoW | PEMBROLIZUMAB, KEYTRUDA (pembrolizumab, MK-3475), Lenvatinib, MK-3475, E7080, Solution for infusion, Capsule, hard, KEYTRUDA (pembrolizumab, MK-3475) | Merck Sharp & Dohme LLC, Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc., Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., MERCK SHARP & DOHME CORP. UNA SUSSIDIARIA DI MERCK & CO. INC., Merck Sharp & Dohme LLC, Eisai Ltd, Merck Sharp & Dohme Corp.LLC, a subsidiary of Merck & Co., Inc., Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Merck Sharp & Dohme LLC., Eisai Ltd. | Unresectable Stage III and Stage IV melanoma, Advanced melanoma, Diseases [C] - Cancer [C04] | | | | |
2018-002983-26: Phase 3 Study of Lenvatinib (E7080/MK-7902) plus Pembrolizumab (MK- 3475) for First-line Therapy of Advanced Hepatocellular Carcinoma |
|
|
| Not yet recruiting | 3 | 750 | Europe | PEMBROLIZUMAB, KEYTRUDA (pembrolizumab, MK-3475), Lenvatinib, MK-3475, E7080, Solution for infusion, Capsule, hard, KEYTRUDA (pembrolizumab, MK-3475) | Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Merck Sharp & Dohme LLC, MERCK SHARP & DOHME CORP. UNA SUSSIDIARIA DI MERCK & CO. INC., Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Eisai Limited., Merck Sharp & Dohme LLC, Eisai Limited, Eisai Ltd., Eisai Ltd | Advanced hepatocellular carcinoma, Advanced hepatocellular carcinoma without any prior systemic treatment, Diseases [C] - Cancer [C04] | | | | |
2018-003009-24: Pembrolizumab and lenvatinib versus chemotherapy for advanced, recurrent, or metastatic endometrial cancer |
|
|
| Not yet recruiting | 3 | 875 | Europe, RoW | KEYTRUDA® (pembrolizumab, MK-3475), PEMBROLIZUMAB, Lenvatinib, Paclitaxel Amneal, Paclitaxel, Carboplatin, Paclitaxel Ever Pharma, MK-3475, E7080; MK-7902, Solution for infusion, Capsule, hard, Concentrate for solution for infusion, Concentrate for solution for injection/infusion, KEYTRUDA® (pembrolizumab, MK-3475), Paclitaxel Amneal, Paclitaxel Ever Pharma | Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc., Merck Sharp & Dohme LLC, Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., MERCK SHARP & DOHME CORP. UNA SUSSIDIARIA DI MERCK & CO. INC., Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc., Eisai Limited, Merck Sharp & Dohme LLC, Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc. | Advanced Endometrial Cancer, Advanced Endometrial Cancer is the cancer of the lining of the uterus (or womb)., Diseases [C] - Cancer [C04] | | | | |
| Active, not recruiting | 3 | 1069 | Europe, Canada, Japan, US, RoW | Lenvatinib, Everolimus, Pembrolizumab, Sunitinib | Eisai Inc., Merck Sharp & Dohme LLC | Renal Cell Carcinoma | 08/20 | 03/26 | | |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
KEYNOTE-775, NCT03517449 / 2017-004387-35: Lenvatinib in Combination With Pembrolizumab Versus Treatment of Physician's Choice in Participants With Advanced Endometrial Cancer (MK-3475-775/E7080-G000-309 Per Merck Standard Convention []) |
|
|
| Active, not recruiting | 3 | 827 | Europe, Canada, Japan, US, RoW | Pembrolizumab, KEYTRUDA®, MK-3475, Lenvatinib, LENVIMA®, Paclitaxel, TAXOL®, Doxorubicin, ADRIAMYCIN® | Eisai Inc., Merck Sharp & Dohme LLC | Endometrial Neoplasms | 10/20 | 02/25 | | |
|
|
|
|
|
|
|
|
|
|
|
|
|
2020-004289-20: A Phase 3 Study of Lenvatinib Plus Pembrolizumab in Previously Treated Participants with Metastatic Colorectal Cancer |
|
|
| Not yet recruiting | 3 | 434 | Europe | Lenvatinib, E7080, Concentrate for solution for infusion, Capsule, hard, Film-coated tablet, KEYTRUDA (pembrolizumab, MK-3475), STIVARGA, LONSURF | Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Merck Sharp & Dohme Corp., a subsidiary of Merck & Co.,Inc | Colorectal Carcinoma, Colorectal cancer, Diseases [C] - Cancer [C04] | | | | |
LEAP-007, NCT03829332 / 2018-003794-98: Efficacy and Safety Study of Pembrolizumab (MK-3475) With or Without Lenvatinib (MK-7902/E7080) in Adults With Programmed Cell Death-Ligand 1 (PD-L1)-Positive Treatment-naïve Nonsmall Cell Lung Cancer (NSCLC) (MK-7902-007/E7080-G000-314/) |
|
|
| Completed | 3 | 623 | Europe, Canada, Japan, US, RoW | Pembrolizumab, MK-3475, KEYTRUDA®, Lenvatinib, MK-7902, E7080, LENVIMA®, Placebo for lenvatinib | Merck Sharp & Dohme LLC, Eisai Inc. | Non-small Cell Lung Cancer | 05/21 | 04/24 | | |
LEAP-007 China Extension, NCT04676412: Efficacy and Safety Study of Pembrolizumab (MK-3475) With or Without Lenvatinib (MK-7902/E7080) in Adults With Programmed Cell Death-Ligand 1 (PD-L1)-Positive Treatment-naïve Nonsmall Cell Lung Cancer (NSCLC) [MK-7902-007/E7080-G000-314/LEAP-007] - China Extension Study |
|
|
| Completed | 3 | 27 | RoW | Pembrolizumab, MK-3475, KEYTRUDA®, Lenvatinib, MK-7902, E7080, LENVIMA®, Placebo for lenvatinib | Merck Sharp & Dohme LLC, Eisai Inc. | Non-small Cell Lung Cancer | 05/21 | 03/24 | | |
LEAP-011, NCT03898180 / 2018-003752-21: Study of First-line Pembrolizumab (MK-3475) With Lenvatinib (MK-7902/E7080) in Urothelial Carcinoma Cisplatin-ineligible Participants Whose Tumors Express Programmed Cell Death-Ligand 1 and in Participants Ineligible for Platinum-containing Chemotherapy (MK-7902-011/E7080-G000-317/ ) |
|
|
| Completed | 3 | 505 | Europe, Canada, Japan, US, RoW | Pembrolizumab, MK-3475, KEYTRUDA®, Lenvatinib, MK-7902, E7080, LENVIMA®, Placebo for lenvatinib | Merck Sharp & Dohme LLC, Eisai Inc. | Urothelial Carcinoma | 07/21 | 05/24 | | |
|
RRHCCLT, NCT04237740: Relenvatinib in the Tatment of Recurrence of Hepatocellular Carcinoma After Liver Transplantation |
|
|
| Not yet recruiting | 3 | 40 | NA | relenvatinib, relenvatinib treatment | RenJi Hospital | Hepatocellular Carcinoma, Liver Transplantation | 01/22 | 11/22 | | |
LEAP-002, NCT03713593: Safety and Efficacy of Lenvatinib (E7080/MK-7902) in Combination With Pembrolizumab (MK-3475) Versus Lenvatinib as First-line Therapy in Participants With Advanced Hepatocellular Carcinoma (MK-7902-002/E7080-G000-311/) |
|
|
| Completed | 3 | 794 | Europe, Canada, Japan, US, RoW | lenvatinib, MK-7902, E7080, LENVIMA®, pembrolizumab, MK-3475, KEYTRUDA®, saline placebo | Merck Sharp & Dohme LLC, Eisai Inc. | Carcinoma, Hepatocellular | 06/22 | 09/24 | | |
|
|
|
NCT04687163: Sorafenib or Lenvatinib Plus HAIC of 130 mg/m² Oxaliplatin, and 5-fu vs Sorafenib or Lenvatinib Plus HAIC of 85mg/m² Oxaliplatin, and 5-fu for Unresectable Advanced HCC: a Randomised Phase 3 Trial |
|
|
| Recruiting | 3 | 400 | RoW | HAIC of 130 mg/m² Oxaliplatin, and 5-fu, HAIC of 85 mg/m² Oxaliplatin, and 5-fu, TKI | Sun Yat-sen University, Kaiping Central Hospital, Guangzhou No.12 People's Hospital | Hepatocellular Carcinoma | 12/22 | 12/22 | | |
NCT04229355: DEB-TACE Plus Lenvatinib or Sorafenib or PD-1 Inhibitor for Unresectable Hepatocellular Carcinoma |
|
|
| Recruiting | 3 | 90 | RoW | DEB-TACE plus Sorafenib, DEB-TACE plus Lenvatinib, DEB-TACE plus PD-1 inhibitor | Guangxi Medical University | Hepatocellular Carcinoma | 12/22 | 12/22 | | |
NCT04053985: The Efficacy of Transarterial Chemoinfusion (TAI) Combine Lenvatinib in Advanced Hepatocellular Carcinoma (HCC) |
|
|
| Recruiting | 3 | 206 | RoW | TAI combine lenvatinib, Lenvatinib | Sun Yat-sen University | Hepatocellular Carcinoma | 12/22 | 12/22 | | |
NCT04053972: The Impact on Recurrence Risk of Adjuvant Lenvatinib for Patients With Hepatocellular Carcinoma And Microvascular Invasion (MVI) After Hepatectomy : A Random, Controlled, Stage III Clinical Trial. |
|
|
| Recruiting | 3 | 377 | RoW | Lenvatinib | Sun Yat-sen University | Hepatocellular Carcinoma | 12/22 | 12/22 | | |
LEAP-003, NCT03820986: Safety and Efficacy Study of Pembrolizumab (MK-3475) Combined With Lenvatinib (MK-7902/E7080) as First-line Intervention in Adults With Advance Melanoma (MK-7902-003/E7080-G000-312/) |
|
|
| Completed | 3 | 674 | Europe, Canada, US, RoW | Pembrolizumab, MK-3475, KEYTRUDA®, Lenvatinib, MK-7902, E7080, LENVIMA®, Placebo for lenvatinib | Merck Sharp & Dohme LLC, Eisai Inc. | Malignant Melanoma | 01/23 | 11/24 | | |
LEAP-003 China Extension, NCT04889118: Safety and Efficacy Study of Pembrolizumab (MK-3475) Combined With Lenvatinib (MK-7902/E7080) as First-line Intervention in Adults With Advanced Melanoma (MK-7902-003/E7080-G000-312/LEAP-003)-China Extension Study |
|
|
| Completed | 3 | 131 | RoW | Pembrolizumab, MK-3475, KEYTRUDA®, Lenvatinib, MK-7902, E7080, LENVIMA®, Placebo for lenvatinib | Merck Sharp & Dohme LLC, Eisai Inc. | Malignant Melanoma | 01/23 | 11/24 | | |
LEAP-017, NCT04776148 / 2020-004289-20: Study of Lenvatinib (MK-7902/E7080) in Combination With Pembrolizumab (MK-3475) Versus Standard of Care in Participants With Metastatic Colorectal Cancer (MK-7902-017/E7080-G000-325/) |
|
|
| Completed | 3 | 480 | Europe, Canada, Japan, US, RoW | pembrolizumab, KEYTRUDA®, MK-3475, lenvatinib, MK-7902, E7080, regorafenib, STIVARGA®, REGONIX®, TAS-102 (trifluridine and tipiracil), LONSURF® | Merck Sharp & Dohme LLC, Eisai Inc. | Colorectal Neoplasms | 02/23 | 09/24 | | |
TACE, NCT03905967: With Lenvatinib Versus Lenvatinib Alone in in First-line Treatment of Advanced HCC |
|
|
| Recruiting | 3 | 336 | RoW | TACE, Lenvatinib | Sun Yat-sen University | Advanced Hepatocellular Carcinoma | 04/23 | 06/23 | | |
LEAP-010, NCT04199104 / 2019-003717-34: A Study of Pembrolizumab (MK-3475) With or Without Lenvatinib (E7080/MK-7902) as First Line (1L) Intervention in a Programmed Cell Death-ligand 1 (PD-L1) Selected Population With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (R/M HNSCC) (MK-7902-010) (KEYNOTE-010) |
|
|
| Active, not recruiting | 3 | 511 | Europe, Canada, Japan, US, RoW | Lenvatinib, E7080, MK-7902, LENVIMA®, Pembrolizumab, MK-3475, Keytruda®, Placebo | Merck Sharp & Dohme LLC, Eisai Inc. | Head and Neck Squamous Cell Carcinoma | 05/23 | 03/25 | | |
LEAP-006, NCT03829319 / 2018-003824-35: Safety and Efficacy Study of Pemetrexed + Platinum Chemotherapy + Pembrolizumab (MK-3475) With or Without Lenvatinib (MK-7902/E7080) as First-line Intervention in Adults With Metastatic Nonsquamous Non-small Cell Lung Cancer (MK-7902-006/E7080-G000-315/) |
|
|
| Completed | 3 | 761 | Europe, Canada, Japan, US, RoW | Pembrolizumab, MK-3475, Carboplatin, Cisplatin, Pemetrexed, Lenvatinib, MK-7902, E7080, Placebo matching lenvatinib | Merck Sharp & Dohme LLC, Eisai Inc. | Nonsquamous Non-small Cell Lung Cancer | 08/23 | 08/24 | | |
|
|
|
LEAP-008, NCT03976375 / 2018-003791-12: Efficacy and Safety of Pembrolizumab (MK-3475) With Lenvatinib (E7080/MK-7902) vs. Docetaxel in Participants With Metastatic Non-Small Cell Lung Cancer (NSCLC) and Progressive Disease (PD) After Platinum Doublet Chemotherapy and Immunotherapy (MK-7902-008/E7080-G000-316/) |
|
|
| Completed | 3 | 422 | Europe, Canada, Japan, US, RoW | Pembrolizumab, MK-3475, KEYTRUDA®, Lenvatinib, MK-7902, E7080, LENVIMA®, Docetaxel, TAXOTERE® | Merck Sharp & Dohme LLC, Eisai Inc. | Metastatic Non-Small Cell Lung Cancer | 08/23 | 08/24 | | |
LEAP-006 China Extension, NCT04716933: Safety and Efficacy Study of Pemetrexed + Platinum Chemotherapy + Pembrolizumab (MK-3475) With or Without Lenvatinib (MK-7902/E7080) as First-line Intervention in Adults With Metastatic Nonsquamous Non-small Cell Lung Cancer (MK-7902-006/E7080-G000-315/LEAP-006)-China Extension Study |
|
|
| Completed | 3 | 201 | RoW | Pembrolizumab, MK-3475, Carboplatin, Cisplatin, Pemetrexed, Lenvatinib, MK-7902, E7080, Placebo matching lenvatinib | Merck Sharp & Dohme LLC, Eisai Inc. | Nonsquamous Non-small Cell Lung Cancer | 08/23 | 08/24 | | |
| Completed | 3 | 842 | Europe, Canada, Japan, US, RoW | Lenvatinib, E7080, MK-7902, LENVIMA®, Pembrolizumab, MK-3475, KEYTRUDA®, Paclitaxel, TAXOL®, ONXAL®, Carboplatin, PARAPLATIN® | Merck Sharp & Dohme LLC, Eisai Inc. | Endometrial Neoplasms | 10/23 | 02/25 | | |
|
NCT05056337: Toripalimab in Combination With Lenvatinib and TACE for Conversion Therapy in Patients With Potentially Resectable HCC |
|
|
| Enrolling by invitation | 3 | 220 | RoW | Lenvatinib 4 MG Oral Capsule [Lenvima], Toripalimab, TACE | Shanghai Zhongshan Hospital | Hepatocellular Carcinoma | 11/23 | 12/23 | | |
ChiCTR2100052460: Camrelizumab plus Lenvatinib versus Lenvatinib as first-line therapy for advanced primary liver cancer: a phase III, multicenter, randomized controlled clinical trial |
|
|
| Not yet recruiting | 3 | 306 | | Camrelizumab plus Lenvatinib ;Lenvatinib | the First Affiliated Hospital, Sun Yat-Sen University; the First Affiliated Hospital, Sun Yat-Sen University, Clinical research funds of the First Affiliated Hospital, Sun Yat-Sen University | Hepatocellular carcinoma | | | | |
NCT06201065: FOLFOX-HAIC Plus Lenvatinib and Toripalimab vs. FOLFOX-HAIC Plus Lenvatinib for Advanced Hepatocellular Carcinoma: a Randomized Controlled and Double-blind Trial |
|
|
| Recruiting | 3 | 200 | RoW | Hepatic arterial infusion chemotherapy, Lenvatinib, Toripalimab, oxaliplatin , fluorouracil, and leucovorin | Sun Yat-sen University | Hepatocellular Carcinoma | 07/25 | 12/26 | | |
NCT05220020: TACE Combined With Lenvatinib Versus TACE Sequential Lenvatinib in the Treatment of Intermediate/Advanced Liver Cancer |
|
|
| Recruiting | 3 | 299 | RoW | TACE(Transcatheter arterial chemoembolization), Lenvatinib, Lenvatinib oral | Sun Yat-sen University | Hepatocellular Carcinoma | 02/24 | 02/25 | | |
| Recruiting | 3 | 1250 | Europe, RoW | Nivolumab, OPDIVO, Ipilimumab, YERVOY, Pembrolizumab, KEYTRUDA, Cabozantinib, CABOMETYX, Axitinib, INLYTA, Lenvatinib, LENVIMA | Gustave Roussy, Cancer Campus, Grand Paris, European Commission, CRIS Cancer Foundation, National Cancer Institute, France, Rennes University Hospital, University Hospital, Essen, Fundació Privada Institut d'Investigació Oncològica de Vall d'Hebron, The Netherlands Cancer Institute, Servicio Madrileño de Salud, Madrid, Spain, Hospital Universitario 12 de Octubre, Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, Medical University of Vienna, FAKULTNI NEMOCNICE OLOMOUC, International Kidney Cancer Coalition, Association pour la Recherche sur les Tumeurs du Rein, Resilience, PRIMAA, Queen Mary University of London | Metastatic Kidney Cancer, Metastatic Kidney Carcinoma | 05/32 | 05/32 | | |
LEAP-001 China Extension, NCT04865289: Pembrolizumab (MK-3475) Plus Lenvatinib (E7080/MK-7902) Versus Chemotherapy for Endometrial Carcinoma (ENGOT-en9 / MK-7902-001) - China Extension Study |
|
|
| Completed | 3 | 130 | RoW | Lenvatinib, E7080, MK-7902, LENVIMA®, Pembrolizumab, MK-3475, KEYTRUDA®, Paclitaxel, TAXOL®, ONXAL®, Carboplatin, PARAPLATIN® | Merck Sharp & Dohme LLC, Eisai Inc. | Endometrial Neoplasms | 10/23 | 01/25 | | |
| Active, not recruiting | 3 | 530 | Europe, RoW | Toripalimab combined with Lenvatinib, Placebo combined with Lenvatinib | Shanghai Junshi Bioscience Co., Ltd., Shanghai Junshi Biosciences Co., Ltd | Advanced Hepatocellular Carcinoma (HCC) | 05/25 | 09/26 | | |
| Enrolling by invitation | 3 | 300 | Europe, Japan, US, RoW | Tislelizumab, BGB-A317, Pamiparib, BGB-290, Temozolomide, Sitravatinib, Ociperlimab, BGB-A1217, BAT1706, Fruquintinib, BGB-15025, Zanidatamab, ZW25, BGB-A445, Surzebiclimab, Lenvatinib, LBL-007 | BeiGene | Advanced Malignancies | 12/26 | 12/26 | | |
NCT06492395: Lenvatinib Plus DEB-TACE and HAIC Vs. Lenvatinib Plus DEB-TACE for Large HCC with PVTT |
|
|
| Recruiting | 3 | 178 | RoW | Len+DEB-TACE+HAIC, Len+DEB-TACE | Second Affiliated Hospital of Guangzhou Medical University | Hepatocellular Carcinoma Non-resectable | 07/26 | 07/27 | | |
AK104-308, NCT06371157: A Study of AK104+Lenvatinib in Combination With Transarterial Chemoembolization (TACE) Versus TACE in Participants With Incurable/Non-metastatic Hepatocellular Carcinoma |
|
|
| Recruiting | 3 | 469 | RoW | AK104, Lenvatinib, TACE, Placebo for AK104, Placebo for Lenvatinib | Akeso | Hepatocellular Carcinoma | 10/25 | 05/26 | | |
STROKER, NCT06726421: Systemic Therapy Alone or with Stereotactic Body Radiotherapy for Oligometastatic Kidney Cancer ( Study) |
|
|
| Recruiting | 3 | 252 | RoW | Stereotactic body radiotherapy (SBRT), Stereotactic ablative radiotherapy, axitinib ± immune checkpoint inhibitors (ICIs), lenvatinib ± ICIs, cabozantinib ± ICIs, sunitinib and pazopanib, Standard systemic therapy | Sun Yat-sen University | Renal Cell Carcinoma (Kidney Cancer), Kidney Cancer Metastatic, Renal Cell Carcinoma Metastatic | 09/30 | 09/33 | | |
IMbrave251, NCT04770896 / 2020-005231-78: A Study of Atezolizumab With Lenvatinib or Sorafenib Versus Lenvatinib or Sorafenib Alone in Hepatocellular Carcinoma Previously Treated With Atezolizumab and Bevacizumab |
|
|
| Active, not recruiting | 3 | 554 | Europe, Canada, Japan, RoW | Atezolizumab, Tecentriq, Lenvatinib, Sorafenib | Hoffmann-La Roche | Unresectable Hepatocellular Carcinoma | 07/25 | 10/25 | | |
Adjuvant-02, NCT06089382: A Study to Evaluate Sintilimab Plus Lenvatinib as Adjuvant Therapy in Hepatocellular Carcinoma With Portal Vein Tumor Thrombosis (PVTT) After Surgical Resection |
|
|
| Not yet recruiting | 3 | 104 | RoW | Sintilimab, IBI 308, Lenvatinib, LENVIMA, Transarterial Chemoembolization (TACE) | Tongji Hospital | Hepatocellular Carcinoma | 11/24 | 11/26 | | |
LEN-TAC, NCT05738616: Lenvatinib Combined With TACE and Camrelizumab in Conversion Resection for Advanced Hepatocellular Carcinoma ( Study) |
|
|
| Recruiting | 3 | 196 | RoW | Lenvatinib combined with TACE and Camrelizumab | Wen Tianfu | Advanced Hepatocellular Carcinoma | 05/27 | 12/27 | | |
ChiCTR2200064384: Efficacy and Safety of Hepatic Arterial Infusion Chemotherapy (HAIC) combined with Lenvatinib and Tislelizumab for Unresectable Hepatocellular Carcinoma |
|
|
| Recruiting | 3 | 50 | | 1 | The Second Affiliated Hospital of Nanchang University; The Second Affiliated Hospital of Nanchang University, The Second Affiliated Hospital of Nanchang University | hepatocellular carcinoma | | | | |
PREVENT-2, NCT05910970: Adjuvant Tislelizumab Plus Lenvatinib for Patients at High-risk of HCC Recurrence After Curative Resection or Ablation |
|
|
| Not yet recruiting | 3 | 200 | RoW | Adjuvant tislelizumab plus lenvatinib, Adjuvant tislelizumab | Guangxi Medical University | Hepatocellular Carcinoma, Recurrence, Immune Checkpoint Inhibitor | 12/25 | 12/25 | | |
| Active, not recruiting | 3 | 534 | Europe, US, RoW | Nofazinlimab (CS1003)+Lenvatinib, Nofazinlimab (CS1003) Placebo+Lenvatinib | CStone Pharmaceuticals | Hepatocellular Carcinoma | 06/25 | 06/25 | | |
ChiCTR2300072771: Clinical study of lenvatinib in the treatment of intermediate stage liver cancer after failure of transcatheter arterial chemoembolization |
|
|
| Not yet recruiting | 3 | 66 | | lenvatinib ;Sorafenib | Beijing Ditan Hospital, Capital Medical University; Beijing Ditan Hospital, Capital Medical University, Beijing Municipal Hospital Scientific Research Cultivation Program | hepatocellular carcinoma | | | | |
NCT05077215: Efficacy and Safety of a Repurposed Drug Added to the Combination of Len Plus Pem in Advanced Endometrial Cancer |
|
|
| Not yet recruiting | 3 | 450 | NA | EG-007, Pembrolizumab 100 mg/ 4 ml (25 mg/ml) Injection, Lenvatinib Capsules | Evergreen Therapeutics, Inc. | Advanced Endometrial Cancer | 12/26 | 12/26 | | |
LEAP-014, NCT04949256 / 2020-001911-26: Efficacy and Safety of Pembrolizumab (MK-3475) Plus Lenvatinib (E7080/MK-7902) Plus Chemotherapy in Participants With Metastatic Esophageal Carcinoma (MK-7902-014/E7080-G000-320/) |
|
|
| Active, not recruiting | 3 | 862 | Europe, Canada, Japan, US, RoW | Pembrolizumab, MK-3475, KEYTRUDA®, Lenvatinib, MK-7902, E7080, LENVIMA®, Cisplatin, PLATINOL®, 5-FU, ADRUCIL®, Oxaliplatin, ELOXATIN®, Leucovorin, calcium folinate, folinic acid, WELLCOVORIN®, Levoleucovorin, calcium levofolinate, levofolinic acid, FUSILEV®, Paclitaxel, TAXOL®, ONXAL® | Merck Sharp & Dohme LLC, Eisai Inc. | Metastatic Esophageal Squamous Cell Carcinoma | 01/27 | 01/27 | | |
|
| Active, not recruiting | 3 | 760 | Europe, Canada, Japan, US, RoW | Tremelimumab, MEDI1123, Durvalumab, MEDI4736, Transarterial Chemoembolization (TACE), DEB-TACE and cTACE, Lenvatinib, Lenvima | AstraZeneca | Hepatocellular Carcinoma | 12/25 | 02/27 | | |
|
|
|
ChiCTR2200066830: Clinical study of TACE combined with lenvatinib plus sintilimab in the treatment of hepatocellular carcinoma with portal vein tumor thrombus |
|
|
| Not yet recruiting | 3 | 218 | | TACE combined with lenvatinib plus sintilimab ;TACE combined with lenvatinib | Beijing Ditan Hospital, Capital Medical University; Beijing Ditan Hospital, Capital Medical University, Capital Health Development Scientific Research Project | Hepatocellular carcinoma | | | | |
ChiCTR2300076242: Canceled by the investigator. Clinical study on the first-line treatment of advanced hepatocellular carcinoma with B-grade liver function using lenvatinib combined with sintilimab and compared to donafenib combined with sintilimab |
|
|
| Not yet recruiting | 3 | 148 | | lenvatinib combined with sintilimab; Donafenib combined with sintilimab | Beijing Ditan Hospital, Capital Medical University; Beijing Ditan Hospital, Capital Medical University, investigator initiated trial (IIT) | hepatocellular carcinoma | | | | |
LEAP-015, NCT04662710 / 2020-001990-53: Efficacy and Safety of Lenvatinib (E7080/MK-7902) Plus Pembrolizumab (MK-3475) Plus Chemotherapy in Participants With Advanced/Metastatic Gastroesophageal Adenocarcinoma (MK-7902-015/E7080-G000-321/) |
|
|
| Active, not recruiting | 3 | 895 | Europe, Canada, Japan, US, RoW | Pembrolizumab, MK-3475, Keytruda®, Lenvatinib, MK-7902, E7080, Oxaliplatin, Capecitabine, Leucovorin (or Levoleucovorin), 5-FU | Merck Sharp & Dohme LLC, Eisai Inc. | Advanced/Metastatic Gastroesophageal Adenocarcinoma | 10/24 | 03/26 | | |
| Active, not recruiting | 3 | 708 | Europe, Canada, Japan, US, RoW | Belzutifan, PT2977, MK-6482, WELIREG™, Lenvatinib, Lenvima, E7080, MK-7902, Cabozantinib, Cabometyx, Cometriq, XL184, BMS-907351 | Merck Sharp & Dohme LLC, Eisai Inc. | Carcinoma, Renal Cell | 02/26 | 02/26 | | |
ChiCTR2400087138: A Phase III, Randomized, Double-blinded, Multicenter Study of Cadonilimab (AK104) + Lenvatinib in Combination With Transarterial Chemoembolization (TACE) Versus TACE in Participants With Incurable/Non-metastatic Hepatocellular Carcinoma |
|
|
| Recruiting | 3 | 469 | | Cadonilimab(AK104) + Lenvatinib+ Transarterial Chemoembolization (TACE); Placebo for AK104+ Placebo for Lenvatinib+ Transarterial Chemoembolization (TACE); Cadonilimab(AK104) + Placebo for Lenvatinib+ Transarterial Chemoembolization (TACE) | Zhongda Hospital Southeast University; Zhongda Hospital Southeast University, Akeso Pharma Co., Ltd. | Hepatocellular carcinoma | | | | |
MK-7902-010 China Extension, NCT05523323: A Study of Pembrolizumab (MK-3475) With or Without Lenvatinib (E7080/MK-7902) as First Line (1L) Intervention in a Programmed Cell Death-ligand 1 (PD-L1) Selected Population With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (R/M HNSCC) (MK-7902-010/LEAP-010)-China Extension |
|
|
| Active, not recruiting | 3 | 112 | RoW | Lenvatinib, E7080, MK-7902, LENVIMA®, Pembrolizumab, MK-3475, Keytruda®, Placebo | Merck Sharp & Dohme LLC, Eisai Inc. | Head and Neck Squamous Cell Carcinoma | 08/23 | 03/25 | | |
| Active, not recruiting | 3 | 732 | Europe, Canada, Japan, US, RoW | Nivolumab, Ipilimumab, Sorafenib, lenvatinib | Bristol-Myers Squibb, Bristol-Myers Squibb International Corporation | Hepatocellular Carcinoma | 09/26 | 09/26 | | |
|
|
|
MK-6482-012, NCT04736706 / 2020-002216-52: A Study of Pembrolizumab (MK-3475) in Combination With Belzutifan (MK-6482) and Lenvatinib (MK-7902), or Pembrolizumab/Quavonlimab (MK-1308A) in Combination With Lenvatinib, Versus Pembrolizumab and Lenvatinib, for Treatment of Advanced Clear Cell Renal Cell Carcinoma |
|
|
| Active, not recruiting | 3 | 1653 | Europe, Canada, Japan, US, RoW | Pembrolizumab, MK-3475, KEYTRUDA®, Belzutifan, MK-6482, PT2977, WELIREG™, Pembrolizumab/Quavonlimab, MK-1308A, Lenvatinib, MK-7902, E7080, LENVIMA® | Merck Sharp & Dohme LLC, Eisai Inc. | Carcinoma, Renal Cell | 10/26 | 10/26 | | |
NCT05608213: Lenvatinib Plus I-125 Seed Brachytherapy vs. Lenvatinib for TACE-refractory HCC |
|
|
| Recruiting | 3 | 187 | RoW | Lenvatinib Plus I-125 Seed Brachytherapy, Lenvatinib | Second Affiliated Hospital of Guangzhou Medical University | Hepatocellular Carcinoma Non-resectable | 10/26 | 12/26 | | |
NCT05608200: Lenvatinib+Sintilimab+TACE vs. Lenvatinib+TACE for Advanced HCC |
|
|
| Recruiting | 3 | 427 | RoW | Lenvatinib, sintilimab plus TACE, Lenvatinib plus TACE | Second Affiliated Hospital of Guangzhou Medical University | Hepatocellular Carcinoma Non-resectable | 10/26 | 10/26 | | |
NCT05823311: Lenvatinib, Tislelizumab Combined with Gemcitabine and Cisplatin (GPLET) in the Treatment of Advanced Cholangiocarcinoma |
|
|
| Recruiting | 3 | 80 | RoW | Lenvatinib, tislelizumab, gemcitabine and cisplatin, Gemcitabine and cisplatin | Second Affiliated Hospital, School of Medicine, Zhejiang University, The First Affiliated Hospital of Zhengzhou University, The Affiliated Tumor Hospital of Xinjiang Medical University | Advanced Cholangiocarcinoma | 12/26 | 12/27 | | |
| Not yet recruiting | 3 | 136 | RoW | Lenvatinib, TACE, SBRT | Sun Yat-sen University | Advanced Hepatocellular Carcinoma | 02/27 | 02/27 | | |
NCT05342194: Toripalimab Plus Lenvatinib and Gemcitabine-based Chemotherapy in 1L Treatment of Advanced ICC: a Phase III Study |
|
|
| Not yet recruiting | 3 | 480 | RoW | Toripalimab, Tuoyi, Lenvatinib mesylate capsules, LENVIMA, Placebo IV, Toripalimab placebo, Oral placebo, Lenvatinib mesylate capsules placebo, Oxaliplatin for injection, Gemcitabine hydrochloride, Cisplatin | Shanghai Junshi Bioscience Co., Ltd. | Intrahepatic Cholangiocarcinoma | 05/27 | 05/27 | | |
MK-6482-012 China Extension, NCT05899049: A Study of Pembrolizumab (MK-3475) in Combination With Belzutifan (MK-6482) and Lenvatinib (MK-7902), or Pembrolizumab/Quavonlimab (MK-1308A) in Combination With Lenvatinib, vs Pembrolizumab and Lenvatinib, for Treatment of Advanced Clear Cell Renal Cell Carcinoma (MK-6482-012)-China Extension Study |
|
|
| Active, not recruiting | 3 | 249 | RoW | Pembrolizumab, MK-3475, KEYTRUDA®, Belzutifan, MK-6482, PT2977, WELIREG™, Pembrolizumab/Quavonlimab, MK-1308A, Lenvatinib, MK-7902, E7080, LENVIMA® | Merck Sharp & Dohme LLC, Eisai Inc. | Carcinoma, Renal Cell | 12/26 | 12/26 | | |
HAIC, NCT06041477: Concurrently vs Sequentially Combined With Targeted and Immunotherapy in Potentially Resectable HCC |
|
|
| Recruiting | 3 | 540 | RoW | Oxaliplatin,calcium folinic acid, levofolinic acid, 5-FU, Hepatic arterial infusion chemotherapy (HAIC), Concurrent Lenvatinib, Concurrent targeted therapy, Concurrent PD-1 antibody, Concurrent immunotherapy, Sequential Lenvatinib, Sequential targeted therapy, Sequential PD-1 antibody, Sequential immunotherapy | Sun Yat-sen University, The First Affiliated Hospital, Guangzhou University of Traditional Chinese Medicine, Affiliated Hospital of Guangdong Medical University, First People's Hospital of Foshan | Hepatocellular Carcinoma, Chemotherapy Effect, Chemotherapeutic Toxicity | 07/27 | 07/30 | | |
NCT05985798: Sintilimab+Bevacizumab+TACE vs. Lenvatinib+TACE for Advanced HCC |
|
|
| Recruiting | 3 | 258 | RoW | Sin-Bev-TACE, Len-TACE | Second Affiliated Hospital of Guangzhou Medical University, Affiliated Hospital of Guangdong Medical University, Zhongshan People's Hospital, Guangdong, China, Lecong Hospital, Shunde District, Foshan, First People's Hospital of Foshan, Affiliated Cancer Hospital & Institute of Guangzhou Medical University | Hepatocellular Carcinoma Non-resectable | 07/27 | 07/27 | | |
LEAP-012, NCT04246177 / 2019-002345-37: Safety and Efficacy of Lenvatinib (E7080/MK-7902) With Pembrolizumab (MK-3475) in Combination With Transarterial Chemoembolization (TACE) in Participants With Incurable/Non-metastatic Hepatocellular Carcinoma (MK-7902-012/E7080-G000-318/) |
|
|
| Active, not recruiting | 3 | 450 | Europe, Japan, US, RoW | Lenvatinib, MK-7902, E7080, LENVIMA®, Pembrolizumab, MK-3475, KEYTRUDA®, Oral Placebo, IV Placebo, TACE | Merck Sharp & Dohme LLC, Eisai Inc. | Carcinoma, Hepatocellular | 06/28 | 12/29 | | |
|
ChiCTR2400090517: An open, multicenter, randomized controlled study of the efficacy and safety of lenvatinib and tirellizumab adjuvant therapy in patients with high-risk relapsing factors for hepatocellular carcinoma |
|
|
| Not yet recruiting | 3 | 328 | | Lenvatinib in combination with tirellizumab; Active monitoring | Affiliated Hospital of Guangdong Medical University; Affiliated Hospital of Guangdong Medical University, Affiliated Hospital of Guangdong Medical University | hepatocellular carcinoma | | | | |
KEYNOTE-587, NCT03486873 / 2017-004417-42: Long-term Safety and Efficacy Extension Study for Participants With Advanced Tumors Who Are Currently on Treatment or in Follow-up in a Pembrolizumab (MK-3475) Study (MK-3475-587/) |
|
|
| Recruiting | 3 | 3500 | Europe, Canada, Japan, US, RoW | Pembrolizumab, MK-3475, KEYTRUDA®, Standard of Care (SOC), Lenvatinib, Olaparib, Lynparza, MK-4280, Favezelimab, MK-4280A | Merck Sharp & Dohme LLC, Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Merck Sharp & Dohme LLC, Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc., MerckSharp&DohmeCorp, a subsidiary of Merck&Co,Inc | Solid Tumors, Hematologic Malignancies | 08/43 | 08/43 | | |
NCT04909866: The Efficacy and Safety of TACE, Lenvatinib and Camrelizumab in the Treatment of BCLC Stage B/C Hepatocellular Carcinoma: a Single-arm, Single-center, Open-label Study |
|
|
| Recruiting | 2/3 | 40 | RoW | TACE+Lenvatininb+Camrelizumab | Wuhan Union Hospital, China | Hepatocellular Carcinoma | 09/22 | 12/22 | | |
NCT04669496: Phase II-III Clinical Trial of PD1 Antibody (Toripalimab), Lenvatinib and GEMOX Neoadjuvant Treatment for Resectable Intrahepatic Cholangiocarcinoma with High-risk Recurrence Factors |
|
|
| Recruiting | 2/3 | 178 | RoW | Neoadjuvant treatment | Shanghai Zhongshan Hospital, Xinhua Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 6th People's Hospital, Shanghai Public Health Clinical Center, RenJi Hospital, Shenzhen University General Hospital | Intrahepatic Cholangiocarcinoma, PD1 Antibody, Lenvatinib, Gemox Chemotherapy | 12/25 | 12/26 | | |
NCT05001724: KN046 Plus Lenvatinib in Subject With Advanced Non-Small Cell Lung Cancer in the Failure of Anti-PD-(L)1 Agent |
|
|
| Terminated | 2/3 | 16 | RoW | KN046, Lenvatinib, Docetaxel | Jiangsu Alphamab Biopharmaceuticals Co., Ltd | Advanced Non-small Cell Lung Cancer | 02/23 | 04/23 | | |
